AstraZeneca PLC (LON:AZN)
12,566
+202 (1.63%)
Jul 15, 2026, 4:38 PM GMT
AstraZeneca Employees
AstraZeneca had 96,100 employees as of December 31, 2025. The number of employees increased by 1,800 or 1.91% compared to the previous year.
Employees
96,100
Change (1Y)
1,800
Growth (1Y)
1.91%
Revenue / Employee
476.28K GBP
Profits / Employee
81.87K GBP
Market Cap
194.90B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96,100 | 1,800 | 1.91% |
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GSK plc | 66,841 |
| Haleon | 24,535 |
| Spire Healthcare Group | 17,800 |
| Smith & Nephew | 16,988 |
| Convatec Group | 10,910 |
| Hikma Pharmaceuticals | 9,400 |
| CVS Group | 9,000 |
| Genus | 3,190 |
AstraZeneca News
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - GlobeNewsWire
- 1 day ago - Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN) - GlobeNewsWire
- 1 day ago - AstraZeneca Secures Licensing Deal for Zegfrovy (AZN) - GuruFocus
- 1 day ago - AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition - GuruFocus
- 1 day ago - AstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M - TheFly
- 1 day ago - AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion - WSJ
- 2 days ago - AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical - Reuters
- 2 days ago - The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions - MarketBeat